Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Names are not enough: a molecular-based information system is the answer
2016-06-03

Description: Department of Plant Sciences staff Tags: Department of Plant Sciences staff

Prof Wijnand Swart (left) from the Department of
Plant Sciences at the UFS and Prof Pedro Crous
from the Centraalbureau voor Schimmelcultures (CBS),
in the Netherlands.
Photo: Leonie Bolleurs

South Africa is the second-largest exporter of citrus in the world, producing 60% of all citrus grown in the Southern Hemisphere. It exports more than 70 % of its citrus crop to the European Union and USA. Not being able to manage fungal pathogens effectively can have a serious impact on the global trade in not only citrus but also other food and fibre crops, such as bananas, coffee, and cacao.

The Department of Plant Sciences at the University of the Free State (UFS) hosted a public lecture by Prof Pedro W. Crous entitled “Fungal Pathogens Impact Trade in Food and Fibre: The Need to Move Beyond Linnaeus” on the Bloemfontein Campus.

Prof Crous is Director of the world’s largest fungal Biological Resource Centre, the Centraalbureau voor Schimmelcultures (CBS), in the Netherlands. He is also one of the top mycologists in the world.

Since the topic of his lecture was very pertinent to food security and food safety worldwide, it was co-hosted by the Collaborative Consortium for Broadening the Food Base, a multi-institutional research programme managed by Prof Wijnand Swart in the Department of Plant Sciences.

Reconsider the manner in which pathogens are identified

Prof Crous stressed that, because international trade in products from agricultural crops will expand, the introduction of fungal pathogens to new regions will increase. “There is therefore an urgent need to reconsider the manner in which these pathogens are identified and treated,” he said.

According to Prof Crous, the older Linnaean system for naming living organisms cannot deal with future trade-related challenges involving pests and pathogens. A system, able to identify fungi based on their DNA and genetic coding, will equip scientists with the knowledge to know what they are dealing with, and whether it is a friendly or harmful fungus.

Description: The fungus, Botrytis cinerea Tags: The fungus, Botrytis cinerea

The fungus, Botrytis cinerea, cause of grey mould
disease in many fruit crops.
Photo: Prof Wijnand Swart

Embrace the molecular-based information system

Prof Crous said that, as a consequence, scientists must embrace new technologies, such as the molecular-based information system for fungi, in order to provide the required knowledge.

He presented this very exciting system which will govern the manner in which fungal pathogens linked to world trade are described. This system ensures that people from different countries will know with which pathogen they are dealing. Further, it will assist with the management of pathogens, ensuring that harmful pathogens do not spread from one country to another.

More about Prof Pedro Crous


Prof Crous is an Affiliated Professor at six international universities, including the UFS, where he is associated with the Department of Plant Sciences. He has initiated several major activities to facilitate global research on fungal biodiversity, and has published more than 600 scientific papers, many in high impact journals, and authored or edited more than 20 books.

 

 

Biography Prof Pedro Crous
Philosophical Transactions of the Royal Society B


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept